Premium
N‐FORMIMIDOYL THIENAMYCIN: IN VITRO COMPARISON WITH CEFOXITIN AND TOBRAMYCIN AGAINST CLINICAL, BACTERIAL ISOLATES
Author(s) -
DIGRANES ASBJØRN,
DIBB WILLIAM L.,
BEISEN EVA
Publication year - 1983
Publication title -
acta pathologica microbiologica scandinavica series b: microbiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.909
H-Index - 88
eISSN - 1600-0463
pISSN - 0108-0180
DOI - 10.1111/j.1699-0463.1983.tb00023.x
Subject(s) - thienamycin , cefoxitin , microbiology and biotechnology , tobramycin , bacteroides fragilis , chemistry , acinetobacter calcoaceticus , imipenem , agar dilution , acinetobacter , moxalactam , antibiotics , minimum inhibitory concentration , cephalosporin , staphylococcus aureus , biology , bacteria , gentamicin , antibiotic resistance , genetics
The in vitro activity of the novel β‐lactam antibiotic, N‐formimidoyl thienamycin (N‐f thienamycin) has been compared with those of cefoxitin and tobramycin. An agar dilution method was employed. N‐f thienamycin was active against all Enterobacteriaceae isolates (MIC ≤ 4 mg/l). All Pseudomonas aeruginosa isolates were inhibited by 2 mg/l. N‐f thienamycin was also active against Acinetobacter calcoaceticus (96 per cent inhibited by 0.5 mg/l) and Gram‐positive cocci. All enterococci were inhibited by 2 mg/l. The drug was active against Haemophilus influenzae (MIC ≤ 1 mg/l) and the Bacteroides fragilis group (MIC ≤ 0.5 mg/l). Cefoxitin was inactive against most Enterobater and A. calcoaceticus isolates and all P. aeruginosa and enterococcal isolates. Tobramycin was virtually inactive against Gram‐positive cocci other than Staphylococcus aureus. N‐f thienamycin thus has a broad spectrum of in vitro activity, greater than that of cefoxitin and tobramycin, and may therefore be useful in the treatment of serious infection, particularly when the aetiology is unknown.